Halozyme (HALO) Stock Forecast & Price Target

Compare

1,020 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HALO Analyst Ratings

Moderate Buy

5 Buy

3 Hold

1 Sell

Based on 9 analysts giving stock ratings to

Halozyme

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HALO Stock 12 Month Forecast

Average Price Target

$65.67

▲(21.61%Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Halozyme in the last 3 months. The average price target is $65.67 with a high forecast of $79.00 and a low forecast of $47.00. The average price target represents a 21.61% change from the last price of $54.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"43":"$43","80":"$80","52.25":"$52.3","61.5":"$61.5","70.75":"$70.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":79,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$79.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":65.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$65.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$47.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[43,52.25,61.5,70.75,80],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.64,57.43692307692308,59.23384615384615,61.03076923076923,62.82769230769231,64.62461538461538,66.42153846153846,68.21846153846154,70.01538461538462,71.81230769230768,73.60923076923078,75.40615384615384,77.20307692307692,{"y":79,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.64,56.41153846153846,57.183076923076925,57.95461538461539,58.72615384615385,59.49769230769231,60.269230769230774,61.04076923076923,61.81230769230769,62.58384615384615,63.355384615384615,64.12692307692308,64.89846153846153,{"y":65.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.64,54.97538461538461,54.31076923076923,53.646153846153844,52.98153846153846,52.316923076923075,51.652307692307694,50.987692307692306,50.323076923076925,49.65846153846154,48.99384615384616,48.32923076923077,47.66461538461539,{"y":47,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":44.29,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.02,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.05,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.85,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.64,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.15,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.59,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.81,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.64,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.87,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.03,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.64,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$79.00

Average Price Target$65.67

Lowest Price Target$47.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$61

Buy

12.96%

Upside

Reiterated

06/05/25

Halozyme's strong earnings performance and increased guidance are the primary drivers of its high score. Despite a bearish technical outlook, the company's impressive financial performance and strategic initiatives like the share repurchase plan support a positive overall evaluation.

Brendan SmithTD Cowen

TD Cowen

$79

Buy

46.30%

Upside

Reiterated

06/10/25

Halozyme (HALO) Gets a Buy from TD Cowen

Mohit BansalWells Fargo

Wells Fargo

$65

Hold

20.37%

Upside

Reiterated

06/02/25

We rate HALO Equal Weight as we believe the value of the company's current partnerships and anticipated new launches are in the name.

Mitchell KapoorH.C. Wainwright

H.C. Wainwright

$72

Buy

33.33%

Upside

Reiterated

05/29/25

Halozyme's Strategic Positioning and Market Potential Drive Buy Rating

David RisingerLeerink Partners

Leerink Partners

$63→$47

Sell

-12.96%

Downside

Downgraded

05/15/25

Halozyme downgraded to Underperform from Market Perform at LeerinkHalozyme downgraded to Underperform from Market Perform at Leerink

Michael DiFioreEvercore ISI

Evercore ISI

$55

Buy

1.85%

Upside

Reiterated

05/15/25

Evercore ISI reiterates Outperform Rating on Halozyme Therapeutics (HALO)Evercore ISI analyst Michael DiFiore reiterated an Outperform rating on Halozyme Therapeutics (NASDAQ: HALO).

Sean LaamanMorgan Stanley

Morgan Stanley

$73→$62

Hold

14.81%

Upside

Downgraded

05/14/25

Hold Rating Issued Amid Uncertainty in Drug Pricing Regulations Impacting Halozyme

Robert WassermanBenchmark Co.

Benchmark Co.

$75

Buy

38.89%

Upside

Reiterated

05/14/25

Optimistic Buy Rating for Halozyme Amid Price Control Concerns

Jason ButlerCitizens JMP

Citizens JMP

$78

Buy

44.44%

Upside

Reiterated

05/14/25

Citizens JMP reiterates Market Outperform Rating on Halozyme Therapeutics (HALO)Citizens JMP analyst Jason Butler reiterated a Market Outperform rating and $78.00 price target on Halozyme Therapeutics (NASDAQ: HALO).

Jessica FyeJ.P. Morgan

J.P. Morgan

$55→$58

Hold

7.41%

Upside

Reiterated

04/21/25

Halozyme Therapeutics (HALO) PT Raised to $58 at JPMorganJPMorgan analyst Jessica Fye raised the price target on Halozyme Therapeutics (NASDAQ: HALO) to $58.00 (from $55.00) while maintaining a Neutral rating.

Joseph CatanzaroPiper Sandler

Piper Sandler

$53

Hold

-1.85%

Downside

Reiterated

03/06/25

Piper Sandler Keeps Their Hold Rating on Halozyme (HALO)

Rajan SharmaGoldman Sachs

Goldman Sachs

―

Hold

―

Reiterated

10/03/24

Halozyme Therapeutics: A Hold Rating Amidst Collaboration Opportunities and Market Uncertainties

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$61

Buy

12.96%

Upside

Reiterated

06/05/25

Brendan SmithTD Cowen

TD Cowen

$79

Buy

46.30%

Upside

Reiterated

06/10/25

Halozyme (HALO) Gets a Buy from TD Cowen

Mohit BansalWells Fargo

Wells Fargo

$65

Hold

20.37%

Upside

Reiterated

06/02/25

We rate HALO Equal Weight as we believe the value of the company's current partnerships and anticipated new launches are in the name.

Mitchell KapoorH.C. Wainwright

H.C. Wainwright

$72

Buy

33.33%

Upside

Reiterated

05/29/25

Halozyme's Strategic Positioning and Market Potential Drive Buy Rating

David RisingerLeerink Partners

Leerink Partners

$63→$47

Sell

-12.96%

Downside

Downgraded

05/15/25

Halozyme downgraded to Underperform from Market Perform at LeerinkHalozyme downgraded to Underperform from Market Perform at Leerink

Michael DiFioreEvercore ISI

Evercore ISI

$55

Buy

1.85%

Upside

Reiterated

05/15/25

Evercore ISI reiterates Outperform Rating on Halozyme Therapeutics (HALO)Evercore ISI analyst Michael DiFiore reiterated an Outperform rating on Halozyme Therapeutics (NASDAQ: HALO).

Sean LaamanMorgan Stanley

Morgan Stanley

$73→$62

Hold

14.81%

Upside

Downgraded

05/14/25

Hold Rating Issued Amid Uncertainty in Drug Pricing Regulations Impacting Halozyme

Robert WassermanBenchmark Co.

Benchmark Co.

$75

Buy

38.89%

Upside

Reiterated

05/14/25

Optimistic Buy Rating for Halozyme Amid Price Control Concerns

Jason ButlerCitizens JMP

Citizens JMP

$78

Buy

44.44%

Upside

Reiterated

05/14/25

Jessica FyeJ.P. Morgan

J.P. Morgan

$55→$58

Hold

7.41%

Upside

Reiterated

04/21/25

Joseph CatanzaroPiper Sandler

Piper Sandler

$53

Hold

-1.85%

Downside

Reiterated

03/06/25

Piper Sandler Keeps Their Hold Rating on Halozyme (HALO)

Rajan SharmaGoldman Sachs

Goldman Sachs

―

Hold

―

Reiterated

10/03/24

Halozyme Therapeutics: A Hold Rating Amidst Collaboration Opportunities and Market Uncertainties

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Halozyme

1 Month

xxx

Success Rate

16/27 ratings generated profit

Average Return

+2.68%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 59.26% of your transactions generating a profit, with an average return of +2.68% per trade.

3 Months

xxx

Success Rate

9/16 ratings generated profit

Average Return

+5.48%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 56.25% of your transactions generating a profit, with an average return of +5.48% per trade.

1 Year

Mitchell KapoorH.C. Wainwright

Success Rate

13/22 ratings generated profit

Average Return

+17.49%

reiterated a buy rating last month

Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 59.09% of your transactions generating a profit, with an average return of +17.49% per trade.

2 Years

xxx

Success Rate

12/16 ratings generated profit

Average Return

+25.58%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +25.58% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HALO Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HALO has received 12 Buy Ratings, 6 Hold Ratings, and 1 Sell Ratings. HALO average Analyst price target in the past 3 months is 65.67.

Each month's total comprises the sum of three months' worth of ratings.

HALO Financial Forecast

HALO Earnings Forecast

Next quarter’s earnings estimate for HALO is $1.21 with a range of $1.10 to $1.30. The previous quarter’s EPS was $1.11. HALO beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.11% of the time in the same period. In the last calendar year HALO has Preformed in-line its overall industry.

HALO Sales Forecast

Next quarter’s sales forecast for HALO is $282.60M with a range of $278.00M to $287.70M. The previous quarter’s sales results were $264.86M. HALO beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year HALO has Preformed in-line its overall industry.

HALO Stock Forecast FAQ

What is HALO’s average 12-month price target, according to analysts?

Based on analyst ratings, Halozyme Therapeutics’s 12-month average price target is 65.67.

What is HALO’s upside potential, based on the analysts’ average price target?

Halozyme Therapeutics has 21.61% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is HALO a Buy, Sell or Hold?

Halozyme Therapeutics has a consensus rating of Moderate Buy which is based on 5 buy ratings, 3 hold ratings and 1 sell ratings.

What is Halozyme Therapeutics’s price target?

The average price target for Halozyme Therapeutics is 65.67. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $79.00 ,the lowest forecast is $47.00. The average price target represents 21.61% Increase from the current price of $54.

What do analysts say about Halozyme Therapeutics?

Halozyme Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of HALO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Halozyme (HALO) Stock Forecast & Price Target

HALO Analyst Ratings

HALO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Halozyme

HALO Analyst Recommendation Trends

HALO Financial Forecast

HALO Earnings Forecast

HALO Sales Forecast

HALO Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts